http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-202037611-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c58a362565a0616bcc3901fcbf9643de |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13a7a0e27c9d5193a1525cb783e13406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_403856861c09a0393a32d5f918345ed9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffa8f156147069e08b8a9d7ee8d06a01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5cf26487fef962883bd90b14bddb9d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dcf91f31d015b35b94b8bb6c6eaf7c9 |
| publicationDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-202037611-A |
| titleOfInvention | Targeted prodrug enzyme fusion carrier and application thereof |
| abstract | The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a precursor drug enzyme, wherein the targeted molecule is selected from the group consisting of arginine-glycine-aspartate amino acid of (RGD) and RGD4C. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. And the targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors. |
| priorityDate | 2019-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1534.